Advertisement
Advertisement
PTCT
PTC Therapeutics, Inc.
66.99
USDSponsored
+0.24
+0.37%
Mar 26, 15:59 UTC -4
Closed
After-Market
66.98
-0.01
-0.01%
PTCT Earnings Reports
Positive Surprise Ratio
PTCT beat 14 of 41 last estimates.
34%
Next Report
Date of Next Report
Apr 23, 2026
Estimate for Q1 26 (Revenue/ EPS)
$229.69M
/-$0.49
Implied change from Q4 25 (Revenue/ EPS)
+7.73%
/-70.66%
Implied change from Q1 25 (Revenue/ EPS)
-80.47%
/-104.89%
PTC Therapeutics, Inc. earnings per share and revenue
On Feb 19, 2026, PTCT reported earnings of -1.67 USD per share (EPS) for Q4 25, missing the estimate of 0.03 USD, resulting in a -4460.31% surprise. Revenue reached 213.20 million, compared to an expected 282.20 million, with a -24.45% difference. The market reacted with a +1.09% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 10 analysts forecast an EPS of -0.49 USD, with revenue projected to reach 229.69 million USD, implying an decrease of -70.66% EPS, and increase of 7.73% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Celcuity Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.06
Actual
-$0.97
Surprise
+8.72%
Precigen, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.24%
Absci Corporation Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.23
Surprise
-16.04%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
LENZ Therapeutics, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.99
Actual
-$1.15
Surprise
-17.10%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
$0.03
Actual
-$0.11
Surprise
-408.12%
Equillium, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.04
Surprise
+35.28%
MaxCyte, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.06
Surprise
+26.47%
TELA Bio, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.16
Surprise
+14.12%
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
FAQ
What were PTC Therapeutics, Inc.'s earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, PTC Therapeutics, Inc. reported EPS of -$1.67, missing estimates by -4460.31%, and revenue of $213.20M, -24.45% below expectations.
How did the market react to PTC Therapeutics, Inc.'s Q4 2025 earnings?
The stock price moved up 1.09%, changed from $69.90 before the earnings release to $70.66 the day after.
When is PTC Therapeutics, Inc. expected to report next?
The next earning report is scheduled for Apr 23, 2026.
What are the forecasts for PTC Therapeutics, Inc.'s next earnings report?
Based on 10
analysts, PTC Therapeutics, Inc. is expected to report EPS of -$0.49 and revenue of $229.69M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement